Literature DB >> 3679918

Radiation therapy for Graves' ophthalmopathy: a retrospective analysis.

D Palmer1, P Greenberg, P Cornell, R G Parker.   

Abstract

A retrospective analysis of 29 patients with Graves' ophthalmopathy treated from 1973-1986 was undertaken to evaluate the use of radiation therapy (RT). Most patients presented with advanced disease; 20 had been treated with steroids and 8 had undergone prior surgery with orbital decompression. Post-RT evaluation was performed by the patients' Radiation Oncologist, Ophthalmologist, and Endocrinologist with a median follow-up period of 45 months. The overall assessment of the patients' disease was judged as improved with respect to the majority of signs and symptoms in 48%. Soft tissue changes were relieved in 78% and proptosis reduced in 52%. Ophthalmoplegia responded poorly and was improved in only 24%. After RT, 26/29 (90%) of patients have had no further steroid requirements. Thirteen patients underwent surgery for residual signs/symptoms post radiation therapy, indicating that combined modality may be necessary in many patients with advanced disease.

Entities:  

Mesh:

Year:  1987        PMID: 3679918     DOI: 10.1016/0360-3016(87)90346-4

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  3 in total

1.  DEGRO practical guidelines for the radiotherapy of non-malignant disorders - Part IV: Symptomatic functional disorders.

Authors:  Gabriele Reinartz; Hans Theodor Eich; Fabian Pohl
Journal:  Strahlenther Onkol       Date:  2014-12-09       Impact factor: 3.621

2.  [Lateral orbitectomy for correction of endocrine ophthalmopathy].

Authors:  H P Howaldt; C Klein; A Dederichs
Journal:  Mund Kiefer Gesichtschir       Date:  1997-05

3.  [Endocrine orbitopathy: comparison of the long-term result and classification after radiotherapy].

Authors:  M H Seegenschmiedt; L Keilholz; G Gusek-Schneider; S Barth; J Hensen; F Wolf; G O Naumann; R Sauer
Journal:  Strahlenther Onkol       Date:  1998-09       Impact factor: 4.033

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.